![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 18, 15666-15670, May 3, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Université Catholique de Louvain, FARL/UCL 54 10, av Hippocrate 54, B-1200 Brussels, Belgium
Received for publication, January 28, 2002, and in revised form, February 21, 2002
Alzheimer disease (AD), the most frequent
cause of dementia, is characterized by an important neuronal loss. A
typical histological hallmark of AD is the extracellular deposition of
A clear diagnosis of AD1
can be performed by correlating clinical findings and postmortem
examination of brain sections. AD is characterized by a massive
neuronal loss in vulnerable brain regions (1, 2). Two typical hallmarks
of AD are neurofibrillary tangles and senile plaques (3). The major
constituent of the amyloid core of senile plaques is the Here, we report that the long term expression of human APP in
rat-cultured neurons induces apoptosis. To understand how APP expression and processing modify neuronal survival, we characterized the extracellular and intracellular A Cell Cultures and Reagents--
Primary cultures of cortical
neurons were prepared from 17-day-old Wistar rat embryos as described
previously (16). Cells were plated in 6- or 96-well culture
dishes (4 × 105 cells/cm2) or glass
coverslips (1.25 × 105 cells/cm2)
pretreated with poly(L-lysine) (10 µg/ml in
phosphate-buffered saline) and cultured for 6 days in vitro
in NEUROBASALTM medium supplemented with 2% B-27 and 0.5 mM L-glutamine prior to infection with
recombinant adenoviruses. Under these conditions, neuronal cultures (up to 98% of neurons) display high differentiation and survival rates (17). Transfected CHO cell lines expressing human APP695
(18) were cultured in F12 medium containing 10% fetal calf serum for
48 h before the culture medium was collected. DAPT, a functional
Recombinant Adenoviruses and Neuronal Infection--
The
construction of recombinant adenoviruses encoding Survival Assays and Nuclear Staining--
Neuronal survival was
measured by the colorimetric MTT assay as described previously (23).
Neurons grown in 96-well culture dishes were incubated after infection
for 2 h at 37 °C in fresh culture medium containing 0.5 mg/ml
MTT. Medium was removed, and dark blue crystals formed were dissolved
by adding 100 µl/well of lysis solution (isopropyl
alcohol/0.04 N HCl). Outer diameter was measured on a
microplate reader (492 nm). For nuclear staining, cells were fixed
(0.37% formaldehyde/0.2% glutaraldehyde in phosphate-buffered saline)
and incubated for 30 min in the Hoechst 33342 dye (1 µg/ml). Nuclear
morphology was analyzed under fluorescence microscopy at
excitation/emission wavelengths of 350/450 nm.
Protein Analysis by Western Blot--
Cell culture medium and
cell lysates were analyzed by Western blot as described previously
(16). Cell lysates (20 µg of protein) and culture medium (15 µl)
were subjected to 10% SDS-PAGE and blotted onto nitrocellulose
membrane, incubated overnight at 4 °C with human APP-specific
primary WO2 antibody at 1 µg/ml (24), washed, and incubated with
1/10,000 anti-mouse Ig horseradish peroxidase-conjugated secondary
antibody followed by ECL revelation.
Immunoprecipitation and Quantification of A Statistical Analysis--
The number of samples (n)
in each experimental condition is indicated in the figure legends.
Statistical analysis was performed by one-way analysis of variance
(ANOVA) followed by Bonferroni's multiple comparison post-test.
Long Term Expression of Human APP in Rat Cortical Neurons Induces
Apoptosis--
When rat cortical neurons are infected by AdRSVAPP or
AdRSV
To further study the mechanism of the neuronal death triggered by human
APP expression, neurons were stained with the Hoechst 3342 nuclear dye.
This morphological analysis of the nuclei allows us to
discriminate between the surviving and the apoptotic cells that display
high nuclear condensation or fragmentation (26). Nuclear morphology of
neurons was analyzed 5 days after infection by AdRSV APP-induced Neuronal Apoptosis Does Not Involve Extracellular APP
and A APP-induced Neuronal Apoptosis Does Not Involve the Intracellular
C-terminal Domain of APP--
A possible origin of APP-induced
neuronal death could be related to the intracellular C-terminal domain
of the protein, which has been demonstrated to induce apoptosis in
other cellular models (27, 28). To test this hypothesis, neurons were
infected with a recombinant adenovirus (AdRSVAPP Intracellular A
To further demonstrate that intraneuronal A It is currently well admitted that APP plays a central role in AD,
but less is known about the link existing between APP processing and
the massive neuronal death that takes place in the disease. In the
present study, we report that long term expression of human APP
triggers apoptosis in rat neurons. This neuronal apoptosis is not
related to the adenoviral-mediated overexpression of an exogenous
protein since the adenoviral-mediated expression of We first investigated the role of secreted A The fact that APP-induced apoptosis occurs independently of secreted
APP derivatives led us to investigate the role of the C-terminal domain
of the protein in neuronal death. The APP C terminus is essential for
the cell surface APP signaling function (36) and for the
APP-dependent axonal anterograde transport (37, 38). Here
we show that the neuronal expression of either C-terminal
deleted APP (APP Another possible origin of APP-induced apoptosis is the intracellular
accumulation of A Intraneuronal A Intraneuronal accumulation of A In conclusion, our data, in agreement with other recent reports,
strongly support the idea that the intraneuronal production and
accumulation of A We thank K. Beyreuther and L. Mercken for the
generous gift of the WO2 antibody and DAPT, respectively. Also, we
acknowledge A. S. Caumont for the critical reading of the manuscript.
*
This work was supported by the Belgian Fonds de la Recherche
Scientifique Médicale, Pôles d'attraction
interuniversitaires/Services fédéraux des Affaires
scientifiques, techniques et culturelles, and the Queen Elisabeth
Medical Foundation.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Published, JBC Papers in Press, February 22, 2002, DOI 10.1074/jbc.M200887200
The abbreviations used are:
AD, Alzheimer
disease;
FAD, familial AD;
APP, amyloid precursor protein;
s
Intracellular Amyloid-
1-42, but Not Extracellular Soluble
Amyloid-
Peptides, Induces Neuronal Apoptosis*
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-amyloid peptide (A
), which is produced by the cleavage of the
amyloid precursor protein (APP). Most of the gene mutations that
segregate with the inherited forms of AD result in increasing the ratio
of A
42/A
40 production. A
42 also accumulates in neurons of AD
patients. Altogether, these data strongly suggest that the neuronal
production of A
42 is a critical event in AD, but the intraneuronal
A
42 toxicity has never been demonstrated. Here, we report that the
long term expression of human APP in rat cortical neurons induces
apoptosis. Although APP processing leads to production of extracellular
A
1-40 and soluble APP, these extracellular derivatives do not
induce neuronal death. On the contrary, neurons undergo apoptosis as soon as they accumulate intracellular A
1-42 following the
expression of full-length APP or a C-terminal deleted APP isoform. The
inhibition of intraneuronal A
1-42 production by a functional
-secretase inhibitor increases neuronal survival. Therefore, the
accumulation of intraneuronal A
1-42 is the key event in the
neurodegenerative process that we observed.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-amyloid or
A
peptide. The A
peptide is a 39-43-amino acid peptide produced
from a larger precursor, the amyloid precursor protein or APP (4).
Among the ten identified isoforms of human APP (5), eight contain the
A
sequence. The isoform that is mainly expressed in the human brain is a 695-amino acid protein known as APP695 (4). APP is processed
by the non-amyloidogenic pathway, where 
secretase activity (6)
produces soluble forms of APP, and by the amyloidogenic pathway, where
-secretase (7) and
-secretase activities allow the release of
A
. Several identified mutations in the APP and the presenilins genes
segregate with inherited forms of AD known as early onset familial
Alzheimer disease or FAD (8, 9). Most of these mutations result in an
increased production of the A
ending at position 42 (10). In
vitro studies have shown that A
42 rapidly aggregates into
fibrils and that extracellular fibrillar A
peptides induce apoptosis
in cultured neurons (11). On the other hand, recent reports have
demonstrated an intraneuronal accumulation of A
42 in AD-vulnerable
brain regions (12, 13). Intraneuronal A
42 accumulation has also been
reported in transgenic mice expressing FAD proteins (14) as well as in
transgenic mice showing accelerated neurodegeneration without
extracellular amyloid deposition (15). Altogether, these data support
the idea that A
42 accumulation and neuronal loss are closely
correlated. Nevertheless, the direct link between A
production by
neurons and neuronal death has not been clearly established until now.
isoforms produced by the processing of different APP constructs. We further demonstrated that
APP-induced neuronal apoptosis depends on intraneuronal A
1-42 accumulation.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-secretase inhibitor (19), was kindly provided by Aventis Pharma.
-galactosidase
(AdRSV
-gal) has been described previously (20, 21). The pAdRSVAPP695
vector was generated by subcloning the EcoRV-SalI fragment of pHMGAPP695 (22) in a pAdRSV vector (20). The deletion of
the APP 695 intracellular domain was generated by PCR amplification of
the APP 695 sequence using a 5' primer (5'-AACGAAGTTGAGCCTGTTGATG-3') encoding residues 560-567 of APP 695 and containing a BglII
restriction site and a 3' primer (5'-GTCGACCTAGTACTGTTTCTTCTTCAGC-3')
complementary to the sequence encoding residues 648-653 followed by a
stop codon and a SalI restriction site. pAdRSVAPP
C was
generated by insertion of the BglII-SalI-digested
PCR product in the BglII-SalI sites of
pAdRSVAPP695. Production, propagation, and purification of adenoviruses
(AdRSVAPP, AdRSVAPP
C, and AdRSV
-gal) were performed as described
previously (20). After 6 days in vitro, neuronal cultures
were infected at the multiplicity of infection of 100 for 4 h in a minimal volume of culture medium. Infection medium was then
replaced by fresh culture medium for 3-5 days. Under these conditions,
at least 75% of neurons express the proteins encoded by recombinant
adenoviruses (16).
Production--
A
production was monitored by immunoprecipitation
of cell culture medium. The quantification of A
1-40 and A
1-42
isoforms was performed by ELISA. Culture medium was collected,
treated with protease inhibitors (1 µg/ml pepstatin, 10 µg/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride), and
cleared by centrifugation (16,000 × g, 5 min,
4 °C). One hundred µl of the supernatant was used for A
quantification by fluorescent sandwich ELISA according to the
manufacturer's instructions (BIOSOURCE,
Camarillo, CA). Previous experiments showed that there is no
cross-reaction between A
1-40 and A
1-42 recognition.
Fluorescence emission was measured at excitation/emission wavelengths
of 485 nm/535 nm. Immunoprecipitation was performed on 1.5 ml of the
remaining culture medium with 15 µl/ml anti-A
whole rabbit serum
(16). The immunoprecipitate was analyzed by Western blot on a 4-12%
NupageTM gel using the WO2 antibody. A
was extracted from cell
lysates by a modification of the protocol described previously (25).
Neurons (~107 cells) were scraped and pelleted in cold
phosphate-buffered saline. Cell pellets were solubilized in 300 µl of
formic acid (70%). Formic acid-solubilized cell pellets were cleared
(16,000 × g, 5 min, 4 °C) to remove cell debris,
and supernatants were centrifuged at 21,000 × g,
4 °C for 20 min. The supernatants were vacuum-dried, and the
resulting pellet was resuspended in 1 ml of alkaline carbonate buffer
(2% Na2CO3, 0.1 N NaOH) and
centrifuged (16,000 × g, 3 min, 4 °C). Protein
concentration was measured on 50 µl of the resulting supernatant by
using the BCA protein assay (Pierce). For immunoprecipitation,
800 µl of the supernatant was neutralized with 800 µl of 1 M Tris-HCl, pH 6.8, and diluted 1:3 in H2O.
Immunoprecipitation was performed as described above. For ELISA, 100 µl of the remaining supernatant was neutralized with 100 µl of 1 M Tris-HCl, pH 6.8, and diluted 1:3 in H2O
containing 10% fetal calf serum, 0.5% Triton X-100, and 0.5% Nonidet
P-40 (final concentrations). A
1-40 and A
1-42 concentrations
were measured by ELISA on 100 µl of neutralized extract.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-gal, a maximal and stable production of APP and
-gal is
observed at day 3 postinfection (16). APP expression and processing
have been analyzed by using the human-specific WO2 antibody (24). Five
days after infection by AdRSVAPP, high levels of soluble human APP
(s
APP) and A
are detected in the culture medium (Fig. 1A). This indicates that human
APP is efficiently processed through both non-amyloidogenic and
amyloidogenic pathways in rat neurons. The extracellular A
was
quantified in the culture medium of neurons expressing human APP (Fig.
1B). These neurons secrete about 100 pg/ml of A
1-40,
but there is no detectable extracellular A
1-42 (not shown). In the
same experimental conditions, the MTT survival assay shows that human
APP expression induces neuronal death, whereas
-gal expression has
no effect (Fig. 1C). Taken together, these results
demonstrate that a 5-day expression and processing of human APP
in rat cortical neurons exert strong neurotoxic effects.

View larger version (40K):
[in a new window]
Fig. 1.
Expression and processing of human APP
triggers apoptosis in rat neurons. A, analysis of
neuronal culture medium 5 days after infection by AdRSVAPP
(APP) or AdRSV 
gal (
-gal). Western
blot (upper panel) showing the accumulation of s
APP in
the culture medium of APP-infected neurons (NI = non-infected) and A
immunoprecipitation (lower panel) of
the same medium. B, quantification of A
production by
ELISA. Under the sensitivity threshold of the test (15 pg/ml), A
is
not detectable (
). Results are given as mean ±S.E.,
(n = 6). C, neuronal survival measured by
MTT assay. Results (mean ±S.E.) are given as the percentage of
survival as compared with non-infected control cultures (**,
p < 0.01, as compared with control; n = 8). D, nuclear morphology analysis (Hoechst 33342 staining) of non-infected (upper panel),
AdRSV
gal-(middle panel), and AdRSVAPP-(lower
panel) infected neurons. The nuclear shape of surviving neurons
(filled arrow) or apoptotic neurons (open arrow)
is indicated. Scale bar = 150 µm. E,
quantification of the morphological analysis. For each condition, 10 fields of 3 independent cultures were analyzed. Results are given as
the percentage of apoptotic neurons per field (**, p < 0.01, as compared with non-infected (NI) control).
-gal or AdRSVAPP
(Fig. 1D), and the results were quantified to compare the
proportion of apoptotic neurons in each condition (Fig. 1E).
There is a 2-fold increase of apoptotic nuclei in neurons expressing
APP as compared with the non-infected or
-gal-expressing neurons.
This establishes that a 5-day expression of human APP induces apoptosis
in rat-cultured neurons.
--
We next analyzed whether the extracellular secretion of
APP and A
could be responsible for the neurotoxic effects observed. To that end, neurons were incubated in the culture medium of a transfected CHO cell line or neuronal cultures expressing human APP695.
The analysis of these two conditioned media indicates that they contain
similar amounts of s
APP but different amounts of A
(Fig.
2A). The quantification of
A
shows that the CHO-conditioned medium contains almost 100-fold
more A
1-40 than the neuronal-conditioned medium. In addition,
A
1-42 is present in the CHO culture medium, whereas it is
undetectable in the neuronal culture medium (Fig. 2B). The
treatment of neurons with these conditioned media does not
significantly modify neuronal survival (Fig. 2C).
Altogether, these results demonstrate that, in our model, the neuronal
apoptosis induced by human APP is not triggered by any APP derivative,
including A
1-40 and A
1-42, secreted in the culture medium. This
raises the hypothesis that intracellular APP derivatives could be
responsible for its neurotoxic effects.

View larger version (18K):
[in a new window]
Fig. 2.
Extracellular APP and A
do not modify neuronal survival. Culture medium from neurons
infected by AdRSVAPP (APP neuron) or from a CHO cell line
stably expressing APP695 (APP CHO) were used to treat
control neurons prior to the survival assay (NI = culture medium of non-infected neurons). A, the presence of
s
APP in the conditioned medium was analyzed, before treatment, by
Western blot (upper panel), and the presence of A
was
monitored by immunoprecipitation (lower panel).
B, quantification by ELISA of the A
present in the
culture medium before treatment (mean ±S.E., n = 3).
C, neuronal survival measured 2 days after treatment
(n = 8).
C) encoding a human
APP isoform deleted in the intracellular C terminus of the
protein. Five days after infection by AdRSVAPP
C, s
APP and A
were detected in the neuronal culture medium (Fig.
3A). Neurons expressing human
APP
C secrete about 50 pg/ml of A
1-40 (Fig. 3B). This
corresponds to half of the concentration of extracellular A
produced
following the expression of full-length APP (Fig. 1B). In
the same experimental conditions, the MTT survival assay shows that
human APP
C expression induces neuronal death (Fig. 3C).
Hoechst staining indicates that APP
C, like APP, triggers neuronal
apoptosis (not shown). Taken together, these results demonstrate that
the intracellular C-terminal domain of human APP is not involved in the
neuronal death observed.

View larger version (24K):
[in a new window]
Fig. 3.
Expression and processing of C-terminal
deleted APP display neurotoxic effects. A, analysis of
neuronal culture medium 5 days after infection by AdRSVAPP
C
(APP
C) or AdRSV
gal (
-gal).
Western blot (upper panel) showing the accumulation of
s
APP in the culture medium of APP
C-infected neurons
(NI = non-infected) and A
immunoprecipitation
(lower panel) of the same culture medium. B,
quantification of A
production by ELISA. Under the sensitivity
threshold of the test (15 pg/ml), A
is not detectable (
). Results
are given as mean ±S.E. (n = 6). C,
neuronal survival measured by MTT assay. Results (mean ±S.E.) are
given as the percentage of survival as compared with non-infected
control cultures (**, p < 0.01, as compared with
control; n = 8).
1-42 Accumulation Induces Neuronal
Apoptosis--
Since the neurotoxic effect of APP does not involve
the intracellular domain of the protein, we investigated whether the
accumulation of intraneuronal A
could trigger apoptosis. An
important fraction of intracellular A
has been shown to be insoluble
(29, 30). Therefore, cells were solubilized in 70% formic acid as
described previously (25) to recover all the intraneuronal A
peptide. The analysis of formic acid-solubilized cell pellets after 3 days of infection by AdRSVAPP or AdRSVAPP
C reveals a similar
expression pattern of the intraneuronal human proteins, although
APP
C is detected in lower amounts as compared with APP (Fig.
4A). In the same experimental
conditions, immunoprecipitation of cellular extracts show that
intraneuronal A
is undetectable (Fig. 4A). The survival
assay shows that, after 3 days of infection, neither APP nor APP
C
expression causes neurotoxic effects (Fig. 4C), indicating
that the overexpression of different levels of APP or APP
C per
se does not induce any neurotoxicity. After 5 days of infection,
neurons still express different amounts of APP or APP
C, but they
accumulate similar amounts of intraneuronal A
1-42. (Fig.
4B) In all these experiments, intraneuronal A
1-40 was
not detectable (not shown). After 5 days, both APP and APP
C induce a
massive neuronal death, as compared with non-infected or
-gal-expressing neurons (Fig. 4D). Taken together, these
results clearly establish that, in our model, APP-induced neuronal
death takes place only when intraneuronal A
1-42 is detected.

View larger version (27K):
[in a new window]
Fig. 4.
APP-induced neuronal death is correlated with
intraneuronal A
1-42 production. Neuronal
cultures were infected by AdRSV
gal (
-gal), AdRSVAPP
(APP), or AdRSVAPP
C (APP
C) for 3 days (3d) or 5 days (5d). A, Western
blot of formic acid-solubilized cell pellets showing the presence of
full-length intraneuronal APP (upper panel) and A
immunoprecipitation of the same cellular extracts (lower
panel). B, quantification of intraneuronal A
1
42
production by ELISA (mean ±S.E., n = 4). C,
neuronal survival measured by MTT assay 3 days after infection. Results
are given as the percentage of neuronal survival as compared with
non-infected control cultures (n = 12). D,
neuronal survival measured by MTT assay 5 days after infection. Results
are given as the percentage of neuronal survival as compared with
non-infected control cultures (**, p < 0.001, as
compared with control or with
-gal; n = 12).
1-42 accumulation leads
to neuronal apoptosis, neurons expressing human APP were treated with
DAPT, a functional
-secretase inhibitor (19). In our experimental
conditions, DAPT does not display significant neurotoxicity by itself
(not shown). Although DAPT treatment does not modify the secretion of
s
APP in the culture medium, it reduces the extracellular A
1
40
concentration to a non-detectable level (Fig.
5A). DAPT also strongly
reduces (57%) the production of intraneuronal A
1-42 without
affecting the levels of APP expression (Fig. 5B). This
reduction of intraneuronal A
1-42 production is concomitant with a
significant recovery (52%) of cell survival (Fig. 5C).
Altogether, these results demonstrate that the neuronal apoptosis
induced by human APP in our model is triggered by the production and
accumulation of intraneuronal A
1-42.

View larger version (26K):
[in a new window]
Fig. 5.
A
-secretase
inhibitor reduces intracellular A
production
and restores neuronal survival. Neuronal cultures were treated for
5 days with 250 nM DAPT immediately after infection with
AdRSVAPP (APP). A, accumulation of s
APP in the
culture medium after 5 days of treatment analyzed by Western blot
(top) and quantification of the extracellular A
release
by ELISA (bottom) under the same conditions (mean ±S.E.,
n = 3). B, analysis of intracellular APP
expression by Western blot (top) and quantification of A
accumulation (bottom) in formic acid-solubilized cell
pellets (mean ±S.E., n = 6). C, neuronal
survival measured by MTT assay 5 days after infection. Results are
given as the percentage of neuronal survival as compared with
non-infected (NI) control cultures (***, p < 0.001, **, p < 0.01; n = 12).
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-galactosidase
is without effect on neuronal survival. Our results are in line with
previous studies showing that the adenoviral expression of human APP695
induces apoptosis in both rat hippocampal neurons (31) and rat brain
(32). It is thus very important to understand how human APP could
induce neuronal death.
in APP-induced
neurotoxicity. We utilized the culture medium of a CHO cell line or
neurons expressing different levels of human APP as a source of
extracellular A
. The concentrations of A
1-40 and A
1-42 in the CHO culture medium are comparable with those measured in the cerebrospinal fluid of AD patients (24). These concentrations of
extracellular A
do not induce any neurotoxicity, indicating that
extracellular soluble A
peptides are not directly responsible for
neurodegeneration. It has been demonstrated previously that extracellular A
must aggregate into fibrils to acquire neurotoxic properties (11). At micromolar concentrations, fibrillar A
provokes
oxidative injuries followed by cell death in neuronal and glial cells
(33, 34). This extracellular A
toxicity could be mediated by the
interaction of fibrillar A
with APP present at the neuronal membrane
(35). In the present study, even when neurons express human APP at
their cell surface, the extracellular A
produced fails to induce
neuronal death.
C) or full-length APP (APP695) induces apoptosis. In
other cellular models, the C-terminal domain of APP has been shown to
mediate cytotoxic effects. The cleavage of the intracellular domain of
APP by caspases generates a C31 cytotoxic fragment in mouse N2a
neuroblastoma cell lines (27). The interaction of the intracellular
domain of the V642I APP mutant with G proteins leads to nucleosomal DNA
fragmentation in F11 neuronal cell lines (28, 39). Since the neuronal
apoptosis observed in this study is not mediated by the C-terminal
domain of APP, we conclude that important differences in the metabolism and function of APP may exist between neuronal primary cultures and
cell lines.
. Neurons have been shown previously to produce
intracellular A
42 (25, 40). Here we report that neurons expressing
human APP or APP
C accumulate very similar amounts of intraneuronal
A
1-42, whereas they produce different amounts of extracellular
A
1-40. The extracellular A
production by neurons expressing APP
or APP
C is in agreement with previous observations in transfected
cells (18, 41). After 3 days of infection, the expression of membrane
human APP or APP
C at different levels does not induce any
neurotoxicity, indicating that the overexpression of APP per
se is not toxic. In addition, the amount of intraneuronal
A
1-42 is probably too low to be detected, and there is no neuronal
damage observed. After 5 days of infection, the intraneuronal
accumulation of A
1-42 in neurons expressing APP or APP
C provokes
a massive neuronal apoptosis. To further demonstrate that intraneuronal
A
1-42 accumulation induces neuronal apoptosis, the intraneuronal
production of A
1-42 was inhibited by a functional
-secretase
inhibitor, DAPT (19). DAPT was chosen among other functional
-secretase inhibitors described (40) because it was the only one
that was not neurotoxic by itself in our experimental conditions.
Moreover, DAPT specifically inhibits A
production without affecting
APP expression and processing through the non-amyloidogenic pathway.
DAPT was able to reduce extracellular A
1-40 production to a
non-detectable level and inhibited intraneuronal A
1-42 production
by 57%. The differential inhibition observed at A
40 and A
42
sites could be viewed as evidence that different
-secretases
generate A
1-40 and A
1-42 or could result from the production of
these two peptides in different cellular organelles to which
-secretase inhibitors have access with different efficiency (42).
The production of intraneuronal APP and A
was studied in three
different experimental conditions: (i) production of APP without
detectable A
1-42, (ii) production of APP and A
1-42, (iii)
production of APP and partial inhibition of the production of
A
1-42. Our results show that the DAPT-mediated inhibition of
intraneuronal A
1-42 accumulation (57%) is similar to the
DAPT-mediated recovery of neuronal survival (52%). This clearly
indicates that the neuronal apoptosis that we observed results from the
accumulation of intraneuronal A
1-42. The mechanisms by which
intraneuronal A
accumulation triggers apoptosis are currently
unknown. The highly amyloidogenic A
1-42 is produced in the
endoplasmic reticulum/intermediate compartment of neuronal cells (43).
The intracellular accumulation of A
1-42 may cause an overload of
the endoplasmic reticulum, leading to neuronal cell injury (44).
accumulation has been described in transgenic mice
expressing FAD mutations. In double transgenic mice expressing human
PS1 and APP mutants, intraneuronal A
accumulation precedes amyloid
deposition (14). Intraneuronal A
42 accumulation together with
extensive neuronal loss occurs without amyloid deposition in transgenic
mice expressing a human PS1 mutation (15). Neuronal loss has also been
documented in transgenic mice expressing the Swedish APP mutation that
leads to plaque formation (45).
42 in AD brains has been recently
reported (12). Although AD patients show a severe neuronal loss in
specific brain regions, the involvement of apoptosis in AD
neurodegeneration remains a matter of debate (46). Apoptotic features
have been observed in brains of AD patients (47), but it may be very
difficult to observe the transient apoptotic state of neurons when
looking at the lesions several years after the onset of the disease.
1-42 are key events in AD. Elucidating how intraneuronal A
triggers apoptosis should in turn allow a better understanding of the neurodegeneration occurring in the disease.
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
To whom correspondence should be addressed. Tel.: 32-2-7649341;
Fax: 32-2-7645460; E-mail: octave@nchm.ucl.ac.be.
![]()
ABBREVIATIONS
APP, soluble human APP;
A
,
-amyloid peptide;
CHO, Chinese hamster
ovary;
ELISA, enzyme-linked immunosorbent assay;
-gal,
-galactosidase;
DAPT, N-[-N-(3,5-difluoro-phenylacetyl)-L-alanyl]-S-phenylglycine
t-butyl ester;
MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide.
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Gomez-Isla, T.,
Hollister, R.,
West, H.,
Mui, S.,
Growdon, J. H.,
Petersen, R. C.,
Parisi, J. E.,
and Hyman, B. T.
(1997)
Ann. Neurol.
41,
17-24[CrossRef][Medline]
[Order article via Infotrieve] 2.
West, M. J.,
Coleman, P. D.,
Flood, D. G.,
and Troncoso, J. C.
(1994)
Lancet
344,
769-772[CrossRef][Medline]
[Order article via Infotrieve] 3.
Braak, H.,
and Braak, E.
(1991)
Acta Neuropathol.
82,
239-259[CrossRef][Medline]
[Order article via Infotrieve] 4.
Kang, J.,
Lemaire, H. G.,
Unterbeck, A.,
Salbaum, J. M.,
Masters, C. L.,
Grzeschik, K. H.,
Multhaup, G.,
Beyreuther, K.,
and Muller-Hill, B.
(1987)
Nature
325,
733-736[CrossRef][Medline]
[Order article via Infotrieve] 5.
Octave, J. N.
(1995)
Rev. Neurosci.
6,
287-316[Medline]
[Order article via Infotrieve] 6.
Lammich, S.,
Kojro, E.,
Postina, R.,
Gilbert, S.,
Pfeiffer, R.,
Jasionowski, M.,
Haass, C.,
and Fahrenholz, F.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
3922-3927 7.
Vassar, R.,
Bennett, B. D.,
Babu-Khan, S.,
Kahn, S.,
Mendiaz, E. A.,
Denis, P.,
Teplow, D. B.,
Ross, S.,
Amarante, P.,
Loeloff, R.,
Luo, Y.,
Fisher, S.,
Fuller, J.,
Edenson, S.,
Lile, J.,
Jarosinski, M. A.,
Biere, A. L.,
Curran, E.,
Burgess, T.,
Louis, J. C.,
Collins, F.,
Treanor, J.,
Rogers, G.,
and Citron, M.
(1999)
Science
286,
735-741 8.
Tanzi, R. E.,
Kovacs, D. M.,
Kim, T. W.,
Moir, R. D.,
Guenette, S. Y.,
and Wasco, W.
(1996)
Neurobiol. Dis.
3,
159-168[CrossRef][Medline]
[Order article via Infotrieve] 9.
George-Hyslop, P. H.
(2000)
Biol. Psychiatry
47,
183-199[CrossRef][Medline]
[Order article via Infotrieve] 10.
Hardy, J.
(1997)
Trends Neurosci.
20,
154-159[CrossRef][Medline]
[Order article via Infotrieve] 11.
Pike, C. J.,
Burdick, D.,
Walencewicz, A. J.,
Glabe, C. G.,
and Cotman, C. W.
(1993)
J. Neurosci.
13,
1676-1687[Abstract] 12.
Gouras, G. K.,
Tsai, J.,
Naslund, J.,
Vincent, B.,
Edgar, M.,
Checler, F.,
Greenfield, J. P.,
Haroutunian, V.,
Buxbaum, J. D., Xu, H.,
Greengard, P.,
and Relkin, N. R.
(2000)
Am. J. Pathol.
156,
15-20 13.
Mochizuki, A.,
Tamaoka, A.,
Shimohata, A.,
Komatsuzaki, Y.,
and Shoji, S.
(2000)
Lancet
355,
42-43[CrossRef][Medline]
[Order article via Infotrieve] 14.
Wirths, O.,
Multhaup, G.,
Czech, C.,
Blanchard, V.,
Moussaoui, S.,
Tremp, G.,
Pradier, L.,
Beyreuther, K.,
and Bayer, T. A.
(2001)
Neurosci. Lett.
306,
116-120[CrossRef][Medline]
[Order article via Infotrieve] 15.
Chui, D. H.,
Tanahashi, H.,
Ozawa, K.,
Ikeda, S.,
Checler, F.,
Ueda, O.,
Suzuki, H.,
Araki, W.,
Inoue, H.,
Shirotani, K.,
Takahashi, K.,
Gallyas, F.,
and Tabira, T.
(1999)
Nat. Med.
5,
560-564[CrossRef][Medline]
[Order article via Infotrieve] 16.
Macq, A. F.,
Czech, C.,
Essalmani, R.,
Brion, J. P.,
Maron, A.,
Mercken, L.,
Pradier, L.,
and Octave, J. N.
(1998)
J. Biol. Chem.
273,
28931-28936 17.
Brewer, G. J.
(1995)
J. Neurosci. Res.
42,
674-683[CrossRef][Medline]
[Order article via Infotrieve] 18.
Essalmani, R.,
Macq, A. F.,
Mercken, L.,
and Octave, J. N.
(1996)
Biochem. Biophys. Res. Commun.
218,
89-96[CrossRef][Medline]
[Order article via Infotrieve] 19.
Dovey, H. F.,
John, V.,
Anderson, J. P.,
Chen, L. Z.,
de Saint, A. P.,
Fang, L. Y.,
Freedman, S. B.,
Folmer, B.,
Goldbach, E.,
Holsztynska, E. J., Hu, K. L.,
Johnson-Wood, K. L.,
Kennedy, S. L.,
Kholodenko, D.,
Knops, J. E.,
Latimer, L. H.,
Lee, M.,
Liao, Z.,
Lieberburg, I. M.,
Motter, R. N.,
Mutter, L. C.,
Nietz, J.,
Quinn, K. P.,
Sacchi, K. L.,
Seubert, P. A.,
Shopp, G. M.,
Thorsett, E. D.,
Tung, J. S., Wu, J.,
Yang, S.,
Yin, C. T.,
Schenk, D. B.,
May, P. C.,
Altstiel, L. D.,
Bender, M. H.,
Boggs, L. N.,
Britton, T. C.,
Clemens, J. C.,
Czilli, D. L.,
Dieckman-McGinty, D. K.,
Droste, J. J.,
Fuson, K. S.,
Gitter, B. D.,
Hyslop, P. A.,
Johnstone, E. M., Li, W. Y.,
Little, S. P.,
Mabry, T. E.,
Miller, F. D., Ni, B.,
Nissen, J. S.,
Porter, W. J.,
Potts, B. D.,
Reel, J. K.,
Stephenson, D., Su, Y.,
Shipley, L. A.,
Whitesitt, C. A.,
Yin, T.,
and Audia, J. E.
(2001)
J. Neurochem.
76,
173-181[CrossRef][Medline]
[Order article via Infotrieve] 20.
Stratford-Perricaudet, L. D.,
Makeh, I.,
Perricaudet, M.,
and Briand, P.
(1992)
J. Clin. Invest.
90,
626-630[Medline]
[Order article via Infotrieve] 21.
Lemarchand, P.,
Jaffe, H. A.,
Danel, C.,
Cid, M. C.,
Kleinman, H. K.,
Stratford-Perricaudet, L. D.,
Perricaudet, M.,
Pavirani, A.,
Lecocq, J. P.,
and Crystal, R. G.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
6482-6486 22.
Czech, C.,
Delaere, P.,
Macq, A. F.,
Reibaud, M.,
Dreisler, S.,
Touchet, N.,
Schombert, B.,
Mazadier, M.,
Mercken, L.,
Theisen, M.,
Pradier, L.,
Octave, J. N.,
Beyreuther, K.,
and Tremp, G.
(1997)
Brain Res. Mol. Brain Res.
47,
108-116[Medline]
[Order article via Infotrieve] 23.
Kienlen-Campard, P.,
Crochemore, C.,
Rene, F.,
Monnier, D.,
Koch, B.,
and Loeffler, J. P.
(1997)
DNA Cell Biol.
16,
323-333[Medline]
[Order article via Infotrieve] 24.
Ida, N.,
Hartmann, T.,
Pantel, J.,
Schroder, J.,
Zerfass, R.,
Forstl, H.,
Sandbrink, R.,
Masters, C. L.,
and Beyreuther, K.
(1996)
J. Biol. Chem.
271,
22908-22914 25.
Skovronsky, D. M.,
Doms, R. W.,
and Lee, V. M.
(1998)
J. Cell Biol.
141,
1031-1039 26.
Edwards, S. N.,
and Tolkovsky, A. M.
(1994)
J. Cell Biol.
124,
537-546 27.
Lu, D. C.,
Rabizadeh, S.,
Chandra, S.,
Shayya, R. F.,
Ellerby, L. M., Ye, X.,
Salvesen, G. S.,
Koo, E. H.,
and Bredesen, D. E.
(2000)
Nat. Med.
6,
397-404[CrossRef][Medline]
[Order article via Infotrieve] 28.
Yamatsuji, T.,
Matsui, T.,
Okamoto, T.,
Komatsuzaki, K.,
Takeda, S.,
Fukumoto, H.,
Iwatsubo, T.,
Suzuki, N.,
Asami-Odaka, A.,
Ireland, S.,
Kinane, T. B.,
Giambarella, U.,
and Nishimoto, I.
(1996)
Science
272,
1349-1352[Abstract] 29.
Yang, A. J.,
Knauer, M.,
Burdick, D. A.,
and Glabe, C.
(1995)
J. Biol. Chem.
270,
14786-14792 30.
Yang, A. J.,
Chandswangbhuvana, D.,
Shu, T.,
Henschen, A.,
and Glabe, C. G.
(1999)
J. Biol. Chem.
274,
20650-20656 31.
Uetsuki, T.,
Takemoto, K.,
Nishimura, I.,
Okamoto, M.,
Niinobe, M.,
Momoi, T.,
Miura, M.,
and Yoshikawa, K.
(1999)
J. Neurosci.
19,
6955-6964 32.
Nishimura, I.,
Uetsuki, T.,
Dani, S. U.,
Ohsawa, Y.,
Saito, I.,
Okamura, H.,
Uchiyama, Y.,
and Yoshikawa, K.
(1998)
J. Neurosci.
18,
2387-2398 33.
Behl, C.,
Davis, J. B.,
Lesley, R.,
and Schubert, D.
(1994)
Cell
77,
817-827[CrossRef][Medline]
[Order article via Infotrieve] 34.
Xu, J.,
Chen, S.,
Ahmed, S. H.,
Chen, H., Ku, G.,
Goldberg, M. P.,
and Hsu, C. Y.
(2001)
J. Neurosci.
21,
RC118 35.
Lorenzo, A.,
Yuan, M.,
Zhang, Z.,
Paganetti, P. A.,
Sturchler-Pierrat, C.,
Staufenbiel, M.,
Mautino, J.,
Vigo, F. S.,
Sommer, B.,
and Yankner, B. A.
(2000)
Nat. Neurosci.
3,
460-464[CrossRef][Medline]
[Order article via Infotrieve] 36.
Neve, R. L.,
McPhie, D. L.,
and Chen, Y.
(2000)
Brain Res.
886,
54-66[CrossRef][Medline]
[Order article via Infotrieve] 37.
Gunawardena, S.,
and Goldstein, L. S.
(2001)
Neuron
32,
389-401[CrossRef][Medline]
[Order article via Infotrieve] 38.
Kamal, A.,
Almenar-Queralt, A.,
LeBlanc, J. F.,
Roberts, E. A.,
and Goldstein, L. S.
(2001)
Nature
414,
643-648[CrossRef][Medline]
[Order article via Infotrieve] 39.
Okamoto, T.,
Takeda, S.,
Murayama, Y.,
Ogata, E.,
and Nishimoto, I.
(1995)
J. Biol. Chem.
270,
4205-4208 40.
Hartmann, T.,
Bieger, S. C.,
Bruhl, B.,
Tienari, P. J.,
Ida, N.,
Allsop, D.,
Roberts, G. W.,
Masters, C. L.,
Dotti, C. G.,
Unsicker, K.,
and Beyreuther, K.
(1997)
Nat. Med.
3,
1016-1020[CrossRef][Medline]
[Order article via Infotrieve] 41.
Koo, E. H.,
and Squazzo, S. L.
(1994)
J. Biol. Chem.
269,
17386-17389 42.
Murphy, M. P.,
Hickman, L. J.,
Eckman, C. B.,
Uljon, S. N.,
Wang, R.,
and Golde, T. E.
(1999)
J. Biol. Chem.
274,
11914-11923 43.
Cook, D. G.,
Forman, M. S.,
Sung, J. C.,
Leight, S.,
Kolson, D. L.,
Iwatsubo, T.,
Lee, V. M.,
and Doms, R. W.
(1997)
Nat. Med.
3,
1021-1023[CrossRef][Medline]
[Order article via Infotrieve] 44.
Paschen, W.,
and Frandsen, A.
(2001)
J. Neurochem.
79,
719-725[CrossRef][Medline]
[Order article via Infotrieve] 45.
Calhoun, M. E.,
Wiederhold, K. H.,
Abramowski, D.,
Phinney, A. L.,
Probst, A.,
Sturchler-Pierrat, C.,
Staufenbiel, M.,
Sommer, B.,
and Jucker, M.
(1998)
Nature
395,
755-756[CrossRef][Medline]
[Order article via Infotrieve] 46.
Cotman, C. W.,
and Su, J. H.
(1996)
Brain Pathol.
6,
493-506[Medline]
[Order article via Infotrieve] 47.
Su, J. H.,
Anderson, A. J.,
Cummings, B. J.,
and Cotman, C. W.
(1994)
Neuroreport
5,
2529-2533[Medline]
[Order article via Infotrieve]
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
R. A. Sharples, L. J. Vella, R. M. Nisbet, R. Naylor, K. Perez, K. J. Barnham, C. L. Masters, and A. F. Hill Inhibition of {gamma}-secretase causes increased secretion of amyloid precursor protein C-terminal fragments in association with exosomes FASEB J, May 1, 2008; 22(5): 1469 - 1478. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Kienlen-Campard, B. Tasiaux, J. Van Hees, M. Li, S. Huysseune, T. Sato, J. Z. Fei, S. Aimoto, P. J. Courtoy, S. O. Smith, et al. Amyloidogenic Processing but Not Amyloid Precursor Protein (APP) Intracellular C-terminal Domain Production Requires a Precisely Oriented APP Dimer Assembled by Transmembrane GXXXG Motifs J. Biol. Chem., March 21, 2008; 283(12): 7733 - 7744. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Lamarca, A. Sanz-Clemente, R. Perez-Pe, M. J. Martinez-Lorenzo, N. Halaihel, P. Muniesa, and J. A. Carrodeguas Two isoforms of PSAP/MTCH1 share two proapoptotic domains and multiple internal signals for import into the mitochondrial outer membrane Am J Physiol Cell Physiol, October 1, 2007; 293(4): C1347 - C1361. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-Y. Lin, T. Gurlo, R. Kayed, A. E. Butler, L. Haataja, C. G. Glabe, and P. C. Butler Toxic Human Islet Amyloid Polypeptide (h-IAPP) Oligomers Are Intracellular, and Vaccination to Induce Anti-Toxic Oligomer Antibodies Does Not Prevent h-IAPP-Induced {beta}-Cell Apoptosis in h-IAPP Transgenic Mice Diabetes, May 1, 2007; 56(5): 1324 - 1332. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Yu, J. Ren, and X. Qu Time-Dependent DNA Condensation Induced by Amyloid {beta}-Peptide Biophys. J., January 1, 2007; 92(1): 185 - 191. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Pierrot, S. F. Santos, C |